Lenalidomide ( DrugBank: Lenalidomide )

8 diseases

ID	Disease name (Link within this page)	Number of trials
16	Crow-Fukase syndrome	6
26	HTLV-1-associated myelopathy	2
28	Systemic amyloidosis	14
34	Neurofibromatosis	1
49	Systemic lupus erythematosus	1
284	Diamond-Blackfan anemia	1
300	IgG4-related disease	1
331	Idiopathic multicentric castleman disease	1

16. Crow-Fukase syndrome

Clinical trials : 13 / Drugs : 14 - (DrugBank : 7) / Drug target genes : 4 - Drug target pathways : 75

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02921893 (ClinicalTrials.gov)	October 31, 2016	26/9/2016	Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome	Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome	Plasmacytoma;POEMS Syndrome	Drug: Dexamethasone;Drug: Ixazomib Citrate;Drug: Lenalidomide;Other: Questionnaire Administration	Mayo Clinic	National Cancer Institute (NCI)	Active, not recruiting	18 Years	N/A	All	21	Early Phase 1	United States
2	NCT02193698 (ClinicalTrials.gov)	July 2014	16/7/2014	Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial	Single Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) Syndrome	POEMS Syndrome	Drug: Lenalidomide+Dexamethasone	Chiba University	NULL	Completed	20 Years	N/A	Both	5	Phase 2	Japan
3	NCT01816620 (ClinicalTrials.gov)	March 2014	14/3/2013	Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome	An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome	POEMS Syndrome	Drug: Lenalidomide, Dexamethasone	Peking Union Medical College Hospital	Celgene Corporation	Completed	18 Years	N/A	All	41	Phase 2	China
4	NCT01639898 (ClinicalTrials.gov)	July 2012	5/7/2012	POEMS Syndrome Treatment With Lenalidomide	Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.	POEMS Syndrome	Drug: Lenalidomide and dexamethasone	University Hospital, Limoges	Ministry of Health, France;Celgene Corporation	Completed	18 Years	N/A	All	51	Phase 2	France
5	EUCTR2008-003202-33-IT (EUCTR)	15/09/2009	17/11/2009	Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002	Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002	POEMS SYNDROME MedDRA version: 9.1;Level: SOC;Classification code 10029205	Trade Name: REVLIMID*21CPS 25MG INN or Proposed INN: Lenalidomide	ISTITUTO CLINICO HUMANITAS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
6	NCT00971685 (ClinicalTrials.gov)	July 2009	3/9/2009	The Treatment of Lenalidomide in Patients With POEMS Syndrome	Evaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS Syndrome	POEMS Syndrome	Drug: Lenalidomide and dexamethasone	Istituto Clinico Humanitas	NULL	Recruiting	18 Years	N/A	Both	16	Phase 2	Italy

26. HTLV-1-associated myelopathy

Clinical trials : 29 / Drugs : 47 - (DrugBank : 29) / Drug target genes : 34 - Drug target pathways : 119

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04301076 (ClinicalTrials.gov)	June 15, 2020	6/3/2020	Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (EPOCH) for Adult T-Cell Leukemia-Lymphoma (ATL)	A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)	Acute Adult T-Cell Leukemia/Lymphoma;Adult T-Cell Leukemia/Lymphoma;Chronic Adult T-Cell Leukemia/Lymphoma;HTLV-1 Infection	Drug: Cyclophosphamide;Drug: Doxorubicin Hydrochloride;Drug: Etoposide;Drug: Lenalidomide;Drug: Prednisone;Drug: Vincristine Sulfate	National Cancer Institute (NCI)	NULL	Recruiting	18 Years	N/A	All	30	Phase 1	United States
2	NCT01274533 (ClinicalTrials.gov)	December 2010	10/1/2011	Lenalidomide in HTLV-1 Adult T-Cell Leukemia	A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma	Adult T Cell Leukemia/Lymphoma	Drug: Lenalidomide	Columbia University	Celgene Corporation	Completed	18 Years	N/A	All	4	Phase 2	United States

28. Systemic amyloidosis

Clinical trials : 267 / Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04298372 (ClinicalTrials.gov)	February 20, 2019	3/12/2019	Frontline Lenalidomide for AL Amyloidosis Involving Myocardium	Frontline Lenalidomide for AL Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide	Amyloidosis Cardiac	Drug: Lenalidomide 25mg	Seoul National University Hospital	NULL	Recruiting	19 Years	99 Years	All	30	Phase 3	Korea, Republic of
2	NCT03252600 (ClinicalTrials.gov)	August 25, 2017	24/7/2017	Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis	A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis	Recurrent Primary Amyloidosis	Drug: Cyclophosphamide;Drug: Dexamethasone;Biological: Elotuzumab;Other: Laboratory Biomarker Analysis;Drug: Lenalidomide;Other: Pharmacological Study	Barbara Ann Karmanos Cancer Institute	National Cancer Institute (NCI);Bristol-Myers Squibb;Multiple Myeloma Research Consortium	Active, not recruiting	18 Years	N/A	All	53	Phase 2	United States
3	NCT01194791 (ClinicalTrials.gov)	October 2010	26/7/2010	Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed	A Multicentric, Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed, Not Candidates for Hematopoietic Stem Cell Transplantation	Primary Systemic Amyloidosis	Drug: Lenalidomide;Drug: Cyclophosphamide;Drug: Dexamethasone	PETHEMA Foundation	NULL	Completed	18 Years	N/A	All	30	Phase 2	Spain
4	NCT00890552 (ClinicalTrials.gov)	April 2009	28/4/2009	A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis	A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis	Leukemia;Amyloidosis	Drug: Lenalidomide;Drug: Melphalan;Drug: Dexamethasone	Stanford University	Celgene Corporation	Completed	18 Years	N/A	All	25	N/A	United States
5	NCT00883623 (ClinicalTrials.gov)	April 2009	15/4/2009	A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis	A Prospective Single Center Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With AL Amyloidosis	Primary Amyloidosis	Drug: Lenalidomide	Heidelberg University	Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH	Completed	18 Years	74 Years	Both	50	Phase 2	Germany
6	EUCTR2008-001405-41-DE (EUCTR)	24/10/2008	28/08/2008	A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEX	A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEX	AL amyloidosis	Trade Name: Revlimid Other descriptive name: Lenalidomide Trade Name: Alkeran Product Code: L01AA03 Other descriptive name: melphalan Trade Name: Fortecortin Other descriptive name: dexamethasone	GMIHO mbH	NULL	Not Recruiting			Female: yes Male: yes			Germany
7	NCT00679367 (ClinicalTrials.gov)	May 2008	14/5/2008	Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis	A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis	Multiple Myeloma	Drug: dexamethasone;Drug: lenalidomide;Drug: melphalan	Boston Medical Center	NULL	Completed	18 Years	N/A	All	16	Phase 2	United States
8	EUCTR2007-006037-13-IT (EUCTR)	21/02/2008	10/12/2007	An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis - ND	An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis - ND	amyloidosis AL MedDRA version: 6.1;Level: PT;Classification code 10002022	Trade Name: Revlimid INN or Proposed INN: Cyclophosphamide INN or Proposed INN: Dexamethasone	OSPEDALE POLICLINICO S. MATTEO	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Italy
9	NCT00981708 (ClinicalTrials.gov)	February 2008	19/9/2009	Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)	A Phase I/II Trial of Lenalidomide Combined With Cyclophosphamide and Intermediate Dose Dexamethasone in Patients With Primary (AL) Systemic Amyloidosis	Amyloidosis	Drug: Lenalidomide, Dexamethasone and Cyclophosphamide	University of Athens	Hellenic Cooperative Oncology Group	Completed	18 Years	N/A	All	37	Phase 1/Phase 2	Greece
10	NCT00607581 (ClinicalTrials.gov)	February 2008	22/1/2008	Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis	An Open-label, Phase II Study of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis	Amyloidosis	Drug: cyclophosphamide;Drug: lenalidomide;Drug: dexamethasone	IRCCS Policlinico S. Matteo	Celgene Corporation	Completed	18 Years	N/A	Both	21	Phase 2	Italy
11	NCT00564889 (ClinicalTrials.gov)	December 2007	28/11/2007	Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis	A Phase II Trial of Lenalidomide (Revlimid®), Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis	Multiple Myeloma and Plasma Cell Neoplasm	Drug: cyclophosphamide;Drug: dexamethasone;Drug: lenalidomide	Mayo Clinic	National Cancer Institute (NCI)	Completed	18 Years	N/A	All	35	Phase 2	United States
12	EUCTR2006-007082-36-GR (EUCTR)	16/10/2007	18/07/2007	A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis - CDR in amyloidosis	A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis - CDR in amyloidosis	Primary (AL) amyloidosis in untreated patients or patientsw who have failed prior treatments	Trade Name: REVLIMID Trade Name: Endoxan Trade Name: Dexamethasone Trade Name: REVLIMID INN or Proposed INN: Lenalidomide INN or Proposed INN: Deaxamethasone INN or Proposed INN: cyclophosphamide	Hellenic Oncology Cooperative Group	NULL	Not Recruiting			Female: yes Male: yes	55	Phase 1/2	Greece
13	NCT00166413 (ClinicalTrials.gov)	April 2005	12/9/2005	Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis	A Phase II Trial of CC-5013 in Patients With Primary Systemic Amyloidosis	Amyloidosis	Drug: CC-5013	Mayo Clinic	NULL	Completed	18 Years	N/A	Both	38	Phase 2	United States
14	NCT00091260 (ClinicalTrials.gov)	January 2004	7/9/2004	CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis	A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis	Multiple Myeloma	Drug: dexamethasone;Drug: lenalidomide	Vaishali Sanchorawala	Celgene Corporation	Completed	18 Years	N/A	All	82	Phase 2	United States

34. Neurofibromatosis

Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01553149 (ClinicalTrials.gov)	March 19, 2012	10/3/2012	Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma	A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas	Neurofibromatosis Type 1;Recurrent Childhood Pilocytic Astrocytoma;Recurrent Childhood Visual Pathway Glioma	Drug: Lenalidomide;Other: Pharmacological Study	National Cancer Institute (NCI)	NULL	Active, not recruiting	N/A	21 Years	All	75	Phase 2	United States;Australia;Canada;New Zealand

49. Systemic lupus erythematosus

Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1900025376	2019-09-01	2019-08-25	Lenalidomide in Treatment-Refractory Lupus-Associated Skin Lesions in Systemic Lupus Erythematosus: A Single-Center, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial	Lenalidomide in Treatment-Refractory Lupus-Associated Skin Lesions in Systemic Lupus Erythematosus: A Single-Center, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial	systemic lupus erythematosus	intervention group:lenalidomide 10mg qd;control group:placebo 10mg qd;	Chinese Academy of Medical Sciences Peking Union Medical College Hospital	NULL	Recruiting	18	70	Both	intervention group:15;control group:15;	Phase 4	China

284. Diamond-Blackfan anemia

Clinical trials : 36 / Drugs : 95 - (DrugBank : 34) / Drug target genes : 23 - Drug target pathways : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01034592 (ClinicalTrials.gov)	November 2009	15/12/2009	Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia	A Pilot Study of Lenalidomide in Adult Diamond-Blackfan Anemia Patients With Red Blood Cell Transfusion-Dependent Anemia	Anemia;Leukemia;Acute Myeloid Leukemia (AML);Myelodysplastic Syndromes (MDS)	Drug: Lenalidomide	Jason Robert Gotlib	Celgene Corporation	Terminated	18 Years	N/A	All	2	Phase 1	United States

300. IgG4-related disease

Clinical trials : 40 / Drugs : 47 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 141

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02705638 (ClinicalTrials.gov)	April 2016	7/3/2016	Treatment of IgG4-Related Disease With Revlimid and Rituximab	Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial	Immunoglobulin G Subclass 4 Related Disease;IgG4-related Disease;Autoimmune Pancreatitis;IgG4-related Sclerosing Cholangitis;Retroperitoneal Fibrosis	Drug: Rituximab;Drug: Lenalidomide	Mayo Clinic	Celgene Corporation	Completed	18 Years	N/A	All	6	Phase 1	United States

331. Idiopathic multicentric castleman disease

Clinical trials : 33 / Drugs : 41 - (DrugBank : 21) / Drug target genes : 22 - Drug target pathways : 123

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100048364	2021-09-01	2021-07-06	A single-arm, prospective, and multicenter study of rituximab combined with lenalidomide in Castleman disease	A single-arm, prospective, and multicenter study of rituximab combined with lenalidomide in Castleman disease	Castleman disease	Treatment group:Rituximab+lenalidomide;	Department of Hematology, Jiangsu Provincial People's Hospital	NULL	Pending	14	90	Both	Treatment group:20;	Phase 4	China